PHARMExcel’s Post

Are you a liver disease researcher looking to expedite your clinical trial? Did you know... Our case-finding tool can help your sites streamline recruitment and answer your preliminary research questions. Some of the first questions for most clinical trials are which population to target, how many sites are needed, and what inclusion/exclusion criteria to set. hepatoSIGHT simplifies this process by quickly and accurately quantifying and characterising the population based on real-world data. This can expedite the recruitment process and ensure that studies can more efficiently enroll participants. hepatoSIGHT can also identify specific hepatic phenotypes, including rare diseases, helping to reduce screen failure rates and ensure researchers work with the most relevant patient cohort for their study. By quickly identifying suitable patients, researchers can conduct their clinical trials more cost-effectively. This not only accelerates the pace of research, but also maximises the impact of the study's findings. To learn more about how hepatoSIGHT can help researchers pave the way in hepatology research, head over to our website 👇 https://lnkd.in/esMJr9wv  #LiverDisease #ClinicalTrials #MedTech

How can we improve outcomes for patients with #liverdisease in the UK? 👉 https://lnkd.in/dkg42TwU to read our full review, published in Frontline Gastroenterology. In the last 5 years, recruitment to #clinicaltrials has significantly dropped across the UK with our global ranking falling from 4th to 10th. It is well documented that patients with liver disease are underserved. Developing new treatments that improve the outcome for this patient group remains an unmet area of clinical need. We're a #CRO in #hepatology and delighted to have collaborated with the UK hepatology community including Oliver Tavabie, Gautam Mehta, Rajiv Jalan, Daniel Green and the UK-Chronic Liver Failure network (UK-CLIF), on a review discussing the challenges and opportunities for innovating #hepatologytrials in the UK, with a focus on improving clinical trial performance and access to #innovative therapies for patients with decompensated #cirrhosis. HOW THIS STUDY MIGHT AFFECT RESEARCH, PRACTICE OR POLICY ⇒ We propose a number of innovations in clinical trial design to improve access to clinical trials for patients, clinicians and investigators alike. ⇒ We highlight the importance of agreeing and implementing standards of care for this patient group, which should not just improve clinical outcomes but reduce heterogeneity in standard of care/placebo cohorts. ⇒ We discuss the potential role of collaboration with industry to improve the delivery of clinical trials. ⇒ We discuss the importance of ensuring the development of the next generation of investigators to ensure sustainability to this model of working. You can read the full review on the PHARMExcel website 👉 https://lnkd.in/dkg42TwU #Gastroenterology #FrontlineGastroenterology #ClinicalResearch Footnote: Image represents an overview of recommendations and themes from the O’Shaughnessy report, NHS. ©️PHARMExcel

How can we improve outcomes for patients with liver disease in the UK? 👉 https://lnkd.in/dkg42TwU to read our full review, published in Frontline Gastroenterology. In the last 5 years, recruitment to #clinicaltrials has significantly dropped across the UK with our global ranking falling from 4th to 10th. It is well documented that patients with #liverdisease are underserved. Developing new treatments that improve the outcome for this patient group remains an unmet area of clinical need. As a #CRO in #hepatology we’re delighted to have collaborated with the UK hepatology community including Oliver Tavabie, Gautam Mehta, Rajiv Jalan, Daniel Green and the UK-Chronic Liver Failure network (UK-CLIF), on a review discussing the challenges and opportunities for innovating #hepatologytrials in the UK, with a focus on improving clinical trial performance and access to #innovative therapies for patients with decompensated #cirrhosis. HOW THIS STUDY MIGHT AFFECT RESEARCH, PRACTICE OR POLICY ⇒ We propose a number of innovations in clinical trial design to improve access to clinical trials for patients, clinicians and investigators alike. ⇒ We highlight the importance of agreeing and implementing standards of care for this patient group, which should not just improve clinical outcomes but reduce heterogeneity in standard of care/placebo cohorts. ⇒ We discuss the potential role of collaboration with industry to improve the delivery of clinical trials. ⇒ We discuss the importance of ensuring the development of the next generation of investigators to ensure sustainability to this model of working. You can read the full review on the PHARMExcel website 👉 https://lnkd.in/dkg42TwU #Gastroenterology #FrontlineGastroenterology #ClinicalResearch Footnote: Image represents an overview of recommendations and themes from the O’Shaughnessy report, NHS. ©️PHARMExcel

**Exciting Research Update!** 🌟 We’ve just published a groundbreaking study on **acute-on-chronic liver failure (#ACLF)**, where we used **machine learning** 🤖 to identify 4️⃣ distinct clusters of patients with different clinical trajectories and survival outcomes. This innovative approach offers new insights that go beyond traditional scoring systems like **MELD** and **CLIF-C ACLF**, and could help transform the management and treatment of ACLF patients. 🩺 📊 By integrating cluster data into existing systems, we were able to boost prognosis accuracy by **11%**! This could significantly impact decision-making around **ICU admissions**, **treatment plans**, and even **liver transplant** discussions. 🏥🫁 Our research is a step forward in understanding the heterogeneity of ACLF, enabling more **personalized care** and **targeted clinical trials**. 🚀 A huge thank you to my amazing co-authors and collaborators 🙌, including Patrick Kamath Dr Duseja Dr Sunil Taneja Dr Akash Roy Dr Arun Valsan and team hepatology pgi and a special shoutout to @aasldtweets @EASLnews @livermatters for their continued support in advancing #Hepatology research. Special thanks to Ihub Anubhuti Foundation supported by DST Government of India 👉 Read the full study here: [https://bit.ly/3XB7YCr] #LiverHealth #AIinHealthcare #Hepatology #ClinicalResearch #MachineLearning #PrecisionMedicine

MOSAIC is the leading MASH/MAFLD Trialists Think Tank. Day 01 will discuss  how to best characterize the cardio-kidney-liver-metabolism (CKLM) intersections. Listen to the discussion to help shape the direction of collaborative, multi-organ, multi-stakeholder clinical trials in MASH/MAFLD. -Opportunities for cross-disorders investigations. The Liver Forum Collaboratory -Industry willingness to share completed trials resources - Metabolic risk stratification -The potential of unbiased phenom mapping using AI and data mining of existing databases. Register now - https://lnkd.in/gsdHgAcu #MOSAIC2024 #ClinicalTrials #NASH #MASH #MAFLD #Multistakeholder #ThinkTank Javed Butler Veronica Miller Faiez Zannad American Gastroenterological Association (AGA) American College of Gastroenterology American Association for the Study of Liver Diseases (AASLD) EASL | The Home of Hepatology European Society of Cardiology Heart Failure Society of America European Association for the Study of Obesity (EASO) European Association for the Study of Diabetes e.V. (EASD) International Diabetes Federation Endocrine Society American Diabetes Association European Society of Endocrinology ICON plc PRA Health Sciences PPD IQVIA Covance Julius Clinical Worldwide Clinical Trials Society for Clinical Research Sites (SCRS) ACRP - Association of Clinical Research Professionals

🔬 Exciting News! 📚 Thrilled to announce that a research paper from our group in IRCCS Policlinico di Sant’Orsola - Azienda Ospedaliero Universitaria di Bologna has been accepted by the Journal of Clinical Medicine (JCM) MDPI 🎉📄 💥 AUTOIMMUNE POLYENDOCRINE SYNDROMES IN ADULT ITALIAN CELIAC DISEASE PATIENTS💥 In this study, we delved into the prevalence of #autoimmune #polyendocrine syndromes in a cohort of patients with #celiac disease. Our findings emphasize the importance of a multidisciplinary management strategy for celiac patients, recognizing the intricate connections between different autoimmune conditions. 🔍 Understanding the "mosaic of autoimmunity" opens new avenues for comprehensive patient care and sheds light on the complex interplay of various autoimmune disorders within the same individual. 🤝 Grateful for the collaboration with fellow researchers and the support of our institution throughout this journey. Special thanks to the "Journal of Clinical Medicine" for providing a platform to share our insights. 📌 Looking forward to contributing more to the field of autoimmune research and advancing patient-centred approaches to healthcare. 💪🏼👩🔬👨⚕️ Free full text: https://lnkd.in/dMx2wDPu #Research #Autoimmunity #CeliacDisease #ClinicalMedicine #Healthcare #MedicalResearch #familyofautoimmunity #mosaicofautoimmunity

Gain knowledge about the Power of Real-World Data (RWD) at MOSAIC 2024! Discover how RWD can drive innovative research in MASH/MAFLD. Join our expert panel on Oct 25 to discuss: - Constructing robust RWD cohorts for meaningful evidence. - Leveraging case studies to understand RWD applications. - Exploring shared placebo cohorts as supplemental controls. - Building a culture of data sharing through the Clinical Research Data Sharing Alliance experience. Shape the future of multi-organ, multi-stakeholder clinical trials in MASH/MAFLD! #MOSAIC2024 #ClinicalTrials #NASH #MASH #MAFLD #Multistakeholder #ThinkTank #WashingtonDC Javed Butler Veronica Miller Faiez Zannad American Gastroenterological Association (AGA) American College of Gastroenterology American Association for the Study of Liver Diseases (AASLD) EASL | The Home of Hepatology European Society of Cardiology Heart Failure Society of America European Association for the Study of Obesity (EASO) European Association for the Study of Diabetes e.V. (EASD) International Diabetes Federation Endocrine Society American Diabetes Association European Society of Endocrinology ICON plc Prashanth Sentilkumar PRA Health Sciences PPD IQVIA Covance Julius Clinical Worldwide Clinical Trials Society for Clinical Research Sites (SCRS) ACRP - Association of Clinical Research Professionals

The recent change in nomenclature from non-alcoholic fatty liver disease (NAFLD) to metabolic dysfunction-associated steatotic liver disease (MASLD) has been paramount in differentiating individuals with hepatic steatosis based on cardiometabolic risk factors and alcohol consumption. This has led to the development of differentiating MASLD from metabolic dysfunction-associated alcoholic liver disease (MetALD) and pure ALD. But what about capturing patients at risk of developing metabolic dysfunction-associated steatohepatitis (MASH)? Our study delineates in the UKB cohort with MRI data that the prevalence of at-risk MASH is the lowest compared to other subtypes, but exhibited the highest risk of liver damage due to elevated aminotransferases, higher BMI and increased hepatic fat retention on imaging. This suggests that this patient population, though underrepresented, are crucial demographics to treat due to the risk of developing advanced-stage liver cancer and end-stage cirrhosis. https://lnkd.in/ewZH5XRK

I'm excited to share our latest publication in Biomedicines, a result of a collaborative effort between gastroenterologists and endocrinologists at University Hospital Dubrava. 🤝🏥 The study focused on type 2 diabetes (T2D) patients, assessing the prevalence of steatosis and compensated advanced chronic liver disease (cACLD) using non-invasive diagnostic methods such as shear wave measurements (SWMs) and attenuation measurements. The research included 214 T2D patients, revealing that 62.6% had steatosis, and 8.9% had cACLD. SWMs demonstrated a strong correlation with vibration-controlled transient elastography (VCTE), making them a reliable diagnostic tool for liver conditions. The study suggests that SWMs could be valuable in diagnosing liver steatosis and cACLD in T2D patients, while further optimization is needed for attenuation measurements. Grateful to my esteemed coauthors for their dedicated collaboration and contributions: Mislav Barišić-Jaman, M.D., Marko Milošević, Viktoria Škurla, David Dohoczky, Petra Dinjar Kujundžić, Maja Cigrovski Berković, Ana Majić-Tengg, Ana Matijaca, Tomo Lucijanić, Mirjana Kardum-Pejić, Vlatka Pandzic Jaksic, Srecko Marusic, Ivica Grgurevic #Research #Collaboration #MedicalScience #Teamwork #Gastroenterology #Endocrinology #ClinicalResearch #UniversityHospitalDubrava The full version of the article is available at: https://lnkd.in/dbYTzBMK

🚨 Highlighted Study: Predictors of Response to Intra-Arterial Vasodilatory Therapy in NOMI 🚨 📄 A key study offers insights into the use of intra-arterial vasodilatory therapy for non-occlusive mesenteric ischemia (NOMI) in patients with severe shock: "Predictors of response to intra-arterial vasodilatory therapy of non-occlusive mesenteric ischemia in patients with severe shock: results from a prospective observational study." (Crit Care. 2022 Apr 04; 26 (1)) 💡 Results could guide the design of future randomized controlled trials to further explore this therapeutic approach for NOMI, potentially improving survival rates in these critically ill patients. Authored by: Nina Rittgerodt, Thorben Pape, Markus Busch, Lena S Becker, Andrea Schneider, Heiner Wedemeyer, Benjamin Seeliger, Julius Schmidt, Anna Maria Hunkemöller, Jan Fuge, Wolfgang Knitsch, Dr. med. Christine Fegbeutel, Hans-Jörg Gillmann, Bernhard Meyer, Marius M Hoeper, Jan B Hinrichs, Prof. Dr. Sascha David, Klaus Stahl. 📚 1.0 #CME available for those interested in this critical research. Read more here: https://lnkd.in/drNpvE2s #CriticalCare #NOMI #VasodilatoryTherapy #ShockManagement #CME